Effects of carvedilol on MDR1-mediated multidrug resistance: Comparison with verapamil

Cancer Science

Volumn 94, Issue 1, 2003, Pages 81-86

  Kakumoto, Mikio ^a   Sakaeda, Toshiyuki ^a   Takara, Kohji ^a   Nakamura, Tsutomu ^a   Kita, Tomoko ^a   Yagami, Tatsurou ^b   Kobayashi, Hironao ^b   Okamura, Noboru ^b   Okumura, Katsuhiko ^a  

^a KOBE UNIVERSITY   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CISPLATIN; COMPLEMENTARY DNA; DAUNORUBICIN; DIGOXIN; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; METOPROLOL TARTRATE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROPRANOLOL; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TRANSPORT; EPITHELIUM CELL; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IC 50; KIDNEY EPITHELIUM; MONOLAYER CULTURE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SWINE; TRANSCYTOSIS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CALCIUM CHANNEL BLOCKERS; CARBAZOLES; CELL DIVISION; CELL LINE; DAUNORUBICIN; DIGOXIN; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; FLUOROURACIL; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY; P-GLYCOPROTEIN; PACLITAXEL; PROPANOLAMINES; SWINE; TRANSFECTION; VERAPAMIL; VINBLASTINE;

EID: 0038324309     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01356.x     Document Type: Article

References (28)

1. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998; 16: 3674-90.
2. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-72.
3. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-24.
4. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-Glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9: 17-24.
5. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44-50.
6. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993; 72: 3553-63.
7. Sikic BI, Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, Halsey J. Clinical reversal of multidrug resistance. In: Goldstein LT, Osols RF, editors. Anticancer drug resistance: advances in molecular and clinical research. Dordrecht: Kluwer Academic; 1994. p. 149-65.
8. Naito S, Kotoh S, Omoto T, Osada Y, Sagiyama K, Iguchi A, Ariyoshi A, Hiratsuka Y, Kumazawa J. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. Cancer Chemother Pharmacol 1998; 42: 367-72.
9. Belpomme D, Gauthier S, Pujade-Lauraine E, Facchini T, Goudier MJ, Krakowski I, Netter-Pinon G, Frenay M, Gousset C, Marié FN, Benmiloud M, Sturtz F. Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Ann Oncol 2000; 11: 1471-6.
10. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K. Interaction of dioxin with antihypertensive drugs via MDR1. Life Sci 2002; 70: 1491-500.
11. Ziemann C, Bürkle A, Kahl GF, Hirsch-Ernst KI. Reactive oxygen species participate in mdr1b mRNA and P-glycoprotein overexpression in primary rat hepatocyte cultures. Carcinogenesis 1999; 20: 407-14.
12. 1). J Pharmacol Exp Ther 1992; 263: 840-5.
13. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992; 267: 24248-52.
14. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K. Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull 1999; 22: 1355-9.
15. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K. Nicardipine and itraconazole inhibited transcellular transport of digoxin. Pharm Pharmacol Commun 2000; 6: 167-71.
16. Dunn CJ, Lea AP, Wagstaff AJ. Carvedilol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1997; 54: 161-85.
17. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free redical scavenger. J Pharmacol Exp Ther 1992; 263: 92-8.
18. Lysko PG, Lysko KA, Yue TL, Webb CL, Gu JL, Feuerstein G. Neuroprotective effects of carvedilol, a new antihypertensive agent, in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke 1992; 23: 1630-6.
19. Feuerstein GZ, Yue TL, Cheng HY, Ruffolo RR Jr. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl 1993; 11: S41-8.
20. Yue TL, McKenna PJ, Gu JL, Cheng HY, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993; 22: 922-8.
21. McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 45: 232-58.
22. McPhillips JJ, Schwemer GT, Scott DI, Zinny M, Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs 1988; 36 Suppl 6: 82-91.
23. Hirsch-Ernst KI, Ziemann C, Schmitz-Salue C, Foth H, Kahl GF. Modulation of P-glycoprotein and mdr1b mRNA expression by growth factors in primary rat hepatocyte culture. Biochem Biophys Res Commun 1995; 215: 179-85.
24. Fardel O, Lecureur V, Daval S, Corlu A, Guillouzo A. Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 1997; 246: 186-92.
25. Zhou G, Kuo MT. NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 1997; 272: 15174-83.
26. Hirsch-Ernst KI, Ziemann C, Foth H, Kozian D, Schmitz-Salue C, Kahl GF. Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J Cell Physiol 1998; 176: 506-15.
27. Sinha BK, Katki AG, Batist G, Cowan KH, Myers CE. Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry 1987; 26: 3776-81.
28. Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB, Rhee SG. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. J Biol Chem 1997; 272: 217-21.